DUBLIN–(BUSINESS WIRE)–New data insights from the Phase 3 teprotumumab trial (OPTIC) will be presented at the ASOPRS Fall Scientific Symposium.
Category: Business
EyeSouth Expands into Central Florida through Affiliation with Central Florida Eye Specialists
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed an affiliation with Central Florida Eye Specialists (“CFES”). The affiliation represents EyeSouth’s third in Florida and first in the…
GenSight Biologics nomme Magali Taiel au poste de Directeur Médical
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitemen…
GenSight Biologics Appoints Magali Taiel as Chief Medical Officer
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative disease…
Stanton Optical, un Proveedor Líder en la Atención de la Vista, Abre Hoy una Nueva Tienda Minorista en San Ángelo
SAN ANGELO, Texas–(BUSINESS WIRE)–Stanton Optical, una marca minorista de Now Optics, que es un proveedor líder de la atención de la vista que ofrece atención oftalmológica accesible y económica, anunció hoy la inauguración de una nueva tienda minori…
PanOptica to Present Positive Topical Anti-VEGF Eye Drop Data at OIS@AAO
MOUNT ARLINGTON, N.J.–(BUSINESS WIRE)–PanOptica announced that the company will present topline data from its Phase 1/2 clinical trial of PAN-90806 at the OIS@AAO on Thurs., Oct. 10, 2019
MyX Therapeutics Presents at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) Conference
MONTREAL–(BUSINESS WIRE)– #MyXdelivery–MyX Therapeutics Inc, a unique enabling mucosal delivery platform company, announces new data from preclinical studies confirming MyX’s mucosal targeting nanoparticle eye drop formulation allows once-a-week dos…
Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting on October 23, 2019
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D.,…
MYX THERAPEUTIQUES PRÉSENTE À LA 9e CONFÉRENCE ANNUELLE SUR LES OPPORTUNITÉS DE PARTENARIAT EN LIVRAISON DE MÉDICAMENTS (PODD)
MONTRÉAL–(BUSINESS WIRE)–MyX Therapeutics Inc, une compagnie offrant une plateforme unique de livraison ciblant les muqueuses, annonce de nouvelles données provenant d’études précliniques confirmant que sa nouvelle formulation, constituée de nanopart…
Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting
LEXINGTON, Mass.–(BUSINESS WIRE)– #aldeyratherapeutics–Aldeyra Therapeutics will discuss its Phase 3 ocular programs on Thursday, October 10 at the Ophthalmology Innovation Summit in San Francisco.
Edmonton-Developed VR Technology Brings Innovative Learning to Eye Institute of Alberta’s Eye Ball Gala
EDMONTON, Alberta–(BUSINESS WIRE)–The Eye Institute of Alberta held their second annual Eye Ball Gala on Sept. 28 where innovative Edmonton-developed VR technology was demonstrated.
Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announc…
Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that the product-specific J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros’ commercial drug marketed for use…
Second Sight Announces $2.4 Million, Four-Year Grant from National Institutes of Health to Develop Spatial Localization and Mapping Technology
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision…
Ophthalmology Drugs: Global Market Forecasts to 2022 Featuring Novartis, Roche, Allergan, Valeant Pharmaceuticals Intl, Bayer, and More – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Drugs Global Market Forecast To 2022” report has been added to ResearchAndMarkets.com’s offering. Where is the largest and fastest growing market for the ophthalmology drugs? How does the market relate to the…
Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing
MALVERN, Pa, & TIANJIN, China–(BUSINESS WIRE)– #Biotechnology–Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
MALVERN, Pa.–(BUSINESS WIRE)– #Biotechnology–Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company.
Aura Biosciences Announces Clinical Data Presentations at the Upcoming American Academy of Ophthalmology 2019 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced multiple data presentations at the upcoming American Academy of Ophthalmology (AAO) 2019 Annual Meeting, be…
Synteract renforce son équipe dirigeante pour les centres de développement de cancérologie et des maladies rares
RESEARCH TRIANGLE PARK, Caroline du Nord–(BUSINESS WIRE)–Synteract, une organisation de recherche sous contrat (ORC) qui s’associe avec des entreprises de biotechnologies et pharmaceutiques pour introduire de nouveaux médicaments sur le marché, a rec…
Synteract erweitert Führungsteam für Entwicklungszentren für Onkologie und seltene Krankheiten
RESEARCH TRIANGLE PARK, North Carolina (USA)–(BUSINESS WIRE)–Synteract, ein innovatives Auftragsforschungsinstitut, das mit Biotech- und Pharmaunternehmen bei der Markteinführung neuer Medikamente zusammenarbeitet, hat zwei erfahrene Führungskräfte e…